my country's pharmaceutical manufacturing industry unveiled a new round of investment in fixed assets

[ Chemical Machinery Equipment Network Market Analysis ] Pharmaceutical companies often need strong capital support in terms of innovation and increasing R&D investment.
In recent years, the development of my country's pharmaceutical manufacturing industry has accelerated, and fixed asset investment in pharmaceutical manufacturing has stabilized, which has helped pharmaceutical manufacturing enterprises to develop and enhance their core competitiveness.
The industry believes that my country's pharmaceutical manufacturing industry is embarking on a new round of fixed asset investment climax.
Under this background, the pharmaceutical machinery industry is expected to fully benefit.

my country's pharmaceutical manufacturing industry unveiled a new round of investment in fixed assets
 

The pharmaceutical manufacturing industry refers to the process in which raw materials become new pharmaceutical products after physical or chemical changes, including the manufacturing of Chinese and Western medicines, veterinary medicines, raw medicines and sanitary materials.
According to the classification, the pharmaceutical manufacturing industry can be divided into seven categories: chemical raw medicine manufacturing, chemical drug preparation manufacturing, Chinese herbal medicine processing, Chinese patent medicine manufacturing, veterinary medicine manufacturing, biological and biochemical products manufacturing, sanitary materials and medical supplies manufacturing.
Subsidiary industry.

 

In recent years, driven by a series of medical reform policies, the development of my country's pharmaceutical manufacturing industry has accelerated.
According to data from the National Bureau of Statistics, in 2020, industrial enterprises above designated size in the pharmaceutical manufacturing industry will achieve operating income of 248.
573 billion yuan, an increase of 4.
5% year-on-year, which is 3.
7% higher than the overall level of industrial enterprises above designated size in the country during the same period.
Incurred operating costs of 1,415.
26 billion yuan, a year-on-year increase of 5.
4%, 4.
8 percentage points higher than the overall level of the national industrial enterprises above designated size in the same period; realized a total profit of 350.
67 billion yuan, a year-on-year increase of 12.
8%, which was 8.
7 percent higher than the overall national level of industrial enterprises above designated size in the same period percentage point.
The profit margin of pharmaceutical manufacturing operating income was approximately 14.
1%, an increase of 1.
1 percentage points from the same period last year, and 8.
0 percentage points higher than the overall level of industrial enterprises above designated size in the country during the same period.

Innovation is the lifeblood of the pharmaceutical industry, but the pharmaceutical industry is a high-input and high-risk industry, so pharmaceutical companies also need strong capital support in the process of increasing research and development efforts.
It is reported that under the impetus of the big health, my country's pharmaceutical manufacturing fixed asset investment maintains stability, helps the development of pharmaceutical manufacturing enterprises, and enhances their core competitiveness.
According to the National Bureau of Statistics, from January to December 2020, the national investment in fixed assets (excluding rural households) was 51,907 trillion yuan, an increase of 2.
9% over the previous year, and the growth rate was 0.
3 percentage points higher than that from January to November.
In terms of different industries, the pharmaceutical manufacturing industry grew rapidly, with investment increasing by 28.
4% over the previous year.  

　　Entering 2021, investment in the pharmaceutical manufacturing industry will continue to grow.
Judging from the investment data from January to April 2021, the national fixed asset investment (excluding rural households) was 14.
38 trillion yuan, a year-on-year increase of 19.
9%; an increase of 8.
0% over the January-April 2019 period, an average increase of 3.
9% over the two years.
Some securities sources pointed out that the manufacturing investment rebounded in the first quarter of this year, with prominent structural characteristics, and the relatively mid-stream industries such as computer electronics and medicine grew at a higher rate.
Data show that the fixed asset investment in the pharmaceutical manufacturing industry from January to April increased by 33.
1% year-on-year.  

　　Regarding the investment strategy in the second half of the year, many fund managers expressed that they are cautiously optimistic about the market in the second half of the year and are optimistic about the direction of good profitability and strong industrial logic.
For example, the advantageous manufacturing industry including medicine can benefit from the improvement of global demand and China.
Increase in corporate share.
In this regard, the industry expects that my country's pharmaceutical manufacturing industry is expected to usher in a new round of fixed asset investment.  

　　The pharmaceutical machinery industry is expected to fully benefit
 

　　The research report recently released by Southwest Securities mentioned that pharmaceutical companies have begun a new round of fixed asset investment, and the growth of the pharmaceutical machinery industry has accelerated, and the year-on-year growth rate has returned to more than 15%.

 

　　It is understood that due to the opening of the new version of GMP in 2011, pharmaceutical companies have increased their investment in fixed assets, and the growth rate of total assets has remained at 15% from 2011 to 2015.
However, starting from 2016, the overall growth rate of fixed assets in the pharmaceutical manufacturing industry has gradually declined.
It was only in 2019 that it gradually resumed its upward trend.
The sales of my country's pharmaceutical machinery industry have also gradually declined after 2015, and have only begun to gradually increase in 2019.
In 2020, the industry sales will reach 19.
7 billion yuan, an increase of 14.
6% year-on-year, and the industry has ushered in an inflection point.  

　　From the perspective of the industry, after more than ten years of development, domestic pharmaceutical equipment companies have gradually moved from low-end to mid-to-high-end manufacturing.
Domestic substitution has accelerated, and the industry has gradually faded away from its cyclical nature to usher in long-term growth.
Under the background that my country's pharmaceutical manufacturing industry has started a new round of fixed asset investment, pharmaceutical companies still have a strong demand for capacity expansion, which will inject new growth momentum into the development of pharmaceutical equipment.  

　　Original title: my country's pharmaceutical manufacturing industry has unveiled a new round of fixed asset investment climax, this industry will have great opportunities